Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK/Valeant Potiga's Discontinuation Rate Could Be Its Undoing

This article was originally published in The Pink Sheet Daily

Executive Summary

Nearly one-third of clinical trial patients taking the antiepileptic had to stop due to adverse events.

You may also be interested in...



Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan

Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.

Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan

Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.

Valeant/GSK's Anti-Epileptic Potiga Faces Advisory Committee In Mid-August

High rate of adverse event-related dropouts in clinical trials could be a key focus of panel's discussion of ezogabine, also known as retigabine.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel